September 07, 2025 a 05:01 pm
RMD: Analysts Ratings - ResMed Inc.
ResMed Inc. continues to maintain a strong market position in the medical devices and healthcare software sector. As of September 2025, the company shows a balanced distribution of positive and cautious analyst ratings, reflecting both solid investor confidence and some concerns regarding market challenges. The majority of recommendations suggest a 'Buy' or 'Hold,' indicating that analysts perceive steady potential growth amidst industry fluctuations.
Historical Stock Grades
The latest analyst ratings for ResMed Inc. in September 2025 reflect cautious optimism. The predominant recommendation category is 'Buy', followed by 'Hold'. The historical data showcases a slight volatility in 'Strong Buy' recommendations, stabilizing after a period of shifts earlier this year.
| Rating Category | Count | Visualization |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 8 | |
| Hold | 6 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, analyst sentiment for ResMed Inc. has seen some fluctuations. The number of total ratings has increased slightly, while the composition has remained relatively stable, with a minor decrease in 'Strong Buy' recommendations. This change suggests a cautious stance towards future growth, with most analysts opting for 'Buy' or 'Hold'.
- The volume of 'Strong Buy' ratings declined slightly over recent months.
- 'Buy' ratings have remained consistently strong, indicating stable growth prospects.
- 'Hold' recommendations have seen minor fluctuations, reflecting both market opportunities and risks.
Percentage Trends
The distribution of ratings reveals a notable shift towards cautious optimism. While 'Strong Buy' ratings have decreased marginally, 'Hold' evaluations have exhibited a slight increase, indicating an increased level of caution. Meanwhile, 'Sell' recommendations remain low, reflecting continued confidence in ResMed’s fundamentals.
- 'Strong Buy' ratings decreased from 13% in early 2025 to 10% by September 2025.
- 'Buy' recommendations maintained approximately 40% of overall ratings.
- 'Hold' ratings indicate a cautious rise from 30% to 33% over recent months.
- The shift reflects a balanced sentiment with a tilt towards cautious optimism as economic conditions evolve.
Latest Analyst Recommendations
Recent analyst reviews show a tendency towards maintaining current ratings, evidencing a stable outlook on ResMed's market position. The following table summarizes the last five recommendations, which are consistent with previous ratings, emphasizing a continuation in sentiment.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-01 | Neutral | Neutral | Piper Sandler |
| 2025-08-01 | Outperform | Outperform | Mizuho |
| 2025-08-01 | Outperform | Outperform | RBC Capital |
| 2025-08-01 | Overweight | Overweight | Keybanc |
| 2025-08-01 | Hold | Hold | Stifel |
Analyst Recommendations with Change of Opinion
The following table highlights the latest analyst recommendations featuring changes in assessment. These transitions reflect the dynamic perspective of the market, demonstrating occasional adjustments in line with market trends and company performance.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-16 | Outperform | Sector Perform | RBC Capital |
| 2025-03-05 | Buy | Neutral | Citigroup |
| 2024-09-18 | Underperform | Peer Perform | Wolfe Research |
| 2024-09-04 | Hold | Buy | Needham |
| 2024-06-25 | Perform | Outperform | Oppenheimer |
Interpretation
From the analysis, it is evident that ResMed Inc. is viewed positively overall by analysts, with a prevailing sentiment of cautious optimism. Although 'Strong Buy' ratings have dropped, the number of 'Buy' and 'Hold' ratings remain strong, underscoring sector confidence despite marginal shifts towards caution. The weighting of recommendations suggests a stable market perception with moderate potential for future growth. Market dynamics and evolving healthcare needs may enhance or shift these ratings in the coming months.
Conclusion
In conclusion, ResMed Inc. presents balanced investment opportunities with solid potential, supported by a consistent analyst endorsement pattern. Despite minor adjustments in rating emphasis, the overall assessment suggests sustainable growth prospects. Analysts’ cautious but stable outlook counters market volatility, reflecting resilience within the medical device sector. However, investors should remain vigilant about emerging macroeconomic factors that could impact market performance and subsequently, analyst ratings.